Skip to content
Screener

OnKure Therapeutics, Inc. OKUR Q4 2025 Annual earnings

Reported March 12, 2026 · Before market open

EPS-$0.99Beat by $0.16
Revenue estimate$16.0M
EPS estimate-$1.15

Next report

Nov 5, 2026 (in 2 months)
Revenue estimate$166.7K
EPS estimate-$0.36

Financials

Q4 2025

Income statement

See full
Operating income-$14.1M+24.5%
Net income-$13.5M+22.6%
EPS (diluted)-$0.99—

Balance sheet

See full
Cash & equivalents$59.1M-46.7%
Total debt$549.0K-49.4%
Total equity$56.2M-45.9%
Total assets$62.1M-45.9%

Cash flow

See full
Operating cash flow-$11.5M+50.7%
CapEx$9.0K-40.0%
Free cash flow-$11.5M+50.7%

Valuation & ratios

Valuation

as of 12/31/25
See full
Market cap$123.71M-65.8%
Enterprise value$65.21M-74.1%

Returns & leverage

See full
Return on equity-74.4%—
Debt / equity0×0.0×
Current ratio10.3×-0.5×

FAQ

When did OnKure Therapeutics, Inc. report Q4 2025 earnings?
OnKure Therapeutics, Inc. (OKUR) reported Q4 2025 earnings on March 12, 2026 before market open.
What were OnKure Therapeutics, Inc.'s Q4 2025 revenue and EPS?
OnKure Therapeutics, Inc. reported eps of $-0.99 for Q4 2025.
Did OnKure Therapeutics, Inc. beat estimates in Q4 2025?
EPS beat the consensus estimate of $-1.15 by $0.16.
How did OnKure Therapeutics, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 27.7% from $-1.37.
Where can I find OnKure Therapeutics, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001193125-26-104104) and the 10-K periodic report (0001193125-26-104147) directly on SEC EDGAR. The filing index links above go to sec.gov.